The pipelines of Puyou are built mainly by internal independent research with proprietary intellectual properties, supported by external co-development and license-in. With a patient-oriented strategy to address unmet medical needs, Puyou develops several novel therapies with different formulations to cover ophthalmic diseases, metabolic diseases, chronic inflammation diseases, and neurodegenerative diseases. We aim to be a pioneer and leader in 2-3 disease areas global wide. Currently Puyou holds the global rights to four first-in-class product candidates, and the Investigational New Drug (IND) application for dry eye disease (DED) was approved by FDA and CDE in 2023 respectively. Phase I study result showed CF04 ophthalmic solution was safe and well tolerated in healthy subjects with no TEAEs related to the investigational product. Currently, proof-of-concept phase II study was initiated in China, and is expected to complete subject enrollment in Mar 2025.
Currently Puyou holds the global rights to four first-in-class product candidates, and the Investigational New Drug (IND) application for dry eye disease (DED) was approved by FDA and CDE in 2023 respectively. Phase I study result showed CF04 ophthalmic solution was safe and well tolerated in healthy subjects with no TEAEs related to the investigational product. Currently, proof-of-concept phase II study was initiated in China, and is expected to complete subject enrollment in Mar 2025.
Follow WeChat